Fulcrum Therapeutics Announces Interim Analysis Data from its ReDUX4 Trial in Facioscapulohumeral Muscular Dystrophy (FSHD)
Reduction in DUX4-driven gene expression observed in biopsies with highest baseline levels of DUX4-driven gene expressionTopline data on-track for Q1 […]